Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 6/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 6/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14291889 | 0.84 | HSP90AA1 (0.36) | CD38HSP90AA1 | |
| SCHEMBL4581166 | 0.82 | HSP90AA1 (0.46) | HSP90AA1 | |
| SCHEMBL14177841 | 0.80 | KCNJ1 (0.39) | TBK1MEN1KMT2AL3MBTL1 | |
| SCHEMBL4580915 | 0.74 | EGLN2 (0.48) | — | |
| SCHEMBL12819925 | 0.73 | PRKCQ (0.39) | PRKCQPRKCDTBK1CD38 | |
| SCHEMBL4580882 | 0.72 | HSP90AA1 (0.46) | PRKCQPRKCDTBK1HSP90AA1 | |
| SCHEMBL14252710 | 0.71 | PRKCQ (0.43) | PRKCQPIM1PRKCDTBK1HSP90AA1 | |
| SCHEMBL3632098 | 0.71 | PRKCQ (0.48) | PRKCQPRKCDMEN1KMT2AL3MBTL1 | |
| SCHEMBL3632100 | 0.71 | PRKCQ (0.48) | PRKCQPRKCDMEN1KMT2AL3MBTL1 | |
| SCHEMBL4582583 | 0.71 | PRKCQ (0.44) | PRKCQPRKCDHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | claimed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, RB1 | PRKCQ 4593/4885PIM1 1374/4885PRKCD 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.